TWI837402B - 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 - Google Patents

含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 Download PDF

Info

Publication number
TWI837402B
TWI837402B TW109124210A TW109124210A TWI837402B TW I837402 B TWI837402 B TW I837402B TW 109124210 A TW109124210 A TW 109124210A TW 109124210 A TW109124210 A TW 109124210A TW I837402 B TWI837402 B TW I837402B
Authority
TW
Taiwan
Prior art keywords
substituted
group
mmol
membered
alkyl
Prior art date
Application number
TW109124210A
Other languages
English (en)
Chinese (zh)
Other versions
TW202135831A (zh
Inventor
段建新
李安蓉
繁英 孟
蔡曉宏
Original Assignee
大陸商深圳艾欣達偉醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商深圳艾欣達偉醫藥科技有限公司 filed Critical 大陸商深圳艾欣達偉醫藥科技有限公司
Publication of TW202135831A publication Critical patent/TW202135831A/zh
Application granted granted Critical
Publication of TWI837402B publication Critical patent/TWI837402B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW109124210A 2019-12-20 2020-07-17 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 TWI837402B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911324466.6 2019-12-20
CN201911324466 2019-12-20

Publications (2)

Publication Number Publication Date
TW202135831A TW202135831A (zh) 2021-10-01
TWI837402B true TWI837402B (zh) 2024-04-01

Family

ID=76477075

Family Applications (4)

Application Number Title Priority Date Filing Date
TW109124210A TWI837402B (zh) 2019-12-20 2020-07-17 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
TW109144974A TWI833055B (zh) 2019-12-20 2020-12-18 抗癌化合物及其醫藥用途
TW113101890A TW202421161A (zh) 2019-12-20 2020-12-18 抗癌化合物及其醫藥用途
TW110133419A TWI893202B (zh) 2019-12-20 2021-09-08 缺氧活化的dna烷化劑及其醫藥用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW109144974A TWI833055B (zh) 2019-12-20 2020-12-18 抗癌化合物及其醫藥用途
TW113101890A TW202421161A (zh) 2019-12-20 2020-12-18 抗癌化合物及其醫藥用途
TW110133419A TWI893202B (zh) 2019-12-20 2021-09-08 缺氧活化的dna烷化劑及其醫藥用途

Country Status (7)

Country Link
US (2) US20230026163A1 (https=)
EP (2) EP4079738A4 (https=)
JP (1) JP2023542286A (https=)
KR (1) KR20230065309A (https=)
CN (2) CN114466853B (https=)
TW (4) TWI837402B (https=)
WO (2) WO2021120717A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
EP4428138A4 (en) * 2021-11-05 2025-08-27 Ascentawits Pharmaceuticals Ltd AKR1C3-ACTIVATED DNA ALKYLATING AGENT AND ITS MEDICAL USE
CN114106042B (zh) * 2021-11-12 2022-09-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN115626938B (zh) * 2022-09-02 2026-04-17 温州医科大学 一种化合物rx4及其在抗结肠癌药物中的作用
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20260009356A (ko) * 2023-05-11 2026-01-19 아센타위츠 파마슈티컬즈 리미티드 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024974A (zh) * 2015-06-24 2018-05-11 分子模板公司 含有dna烷化剂的氮丙啶

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
AU5935600A (en) * 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
WO2004062596A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds having a four carbon backbone
AU2005325676A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2592118C (en) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
CN1948311A (zh) * 2006-11-09 2007-04-18 上海交通大学 2－碘代苯基－6－三氟甲基咪唑并[1,2－a]吡啶－3－乙酰胺类化合物及制备方法
US9278904B2 (en) * 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
CN104098432B (zh) * 2014-06-30 2016-03-30 福建师范大学福清分校 一种三氟甲基化芳烃的合成方法
TWI674258B (zh) * 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Ｄｎａ烷化劑
EP3390415B1 (en) * 2015-11-16 2020-02-26 Obi Pharma, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
CN106279321A (zh) 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
CN107118231B (zh) * 2017-03-17 2019-06-07 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
WO2018184003A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
CN107513057A (zh) 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
WO2020022868A1 (ko) * 2018-07-27 2020-01-30 에스케이이노베이션 주식회사 입자 균일도가 우수한 모데나이트 제올라이트 및 그 제조방법
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024974A (zh) * 2015-06-24 2018-05-11 分子模板公司 含有dna烷化剂的氮丙啶

Also Published As

Publication number Publication date
WO2022052564A1 (zh) 2022-03-17
CN115667278A (zh) 2023-01-31
TW202128188A (zh) 2021-08-01
KR20230065309A (ko) 2023-05-11
TW202210083A (zh) 2022-03-16
WO2021120717A1 (zh) 2021-06-24
TW202421161A (zh) 2024-06-01
EP4079738A4 (en) 2024-04-24
TW202135831A (zh) 2021-10-01
CN114466853A (zh) 2022-05-10
JP2023542286A (ja) 2023-10-06
CN114466853B (zh) 2026-04-14
US20230026163A1 (en) 2023-01-26
EP4079738A1 (en) 2022-10-26
US20230339991A1 (en) 2023-10-26
TWI833055B (zh) 2024-02-21
TWI893202B (zh) 2025-08-11
EP4212538A1 (en) 2023-07-19
EP4212538A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
CN113853379B (zh) 含氟化合物及抗癌医药用途
TWI837402B (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
JP7352297B2 (ja) ピリドン誘導体と、その組成物、並びにそれらが抗ウイルス薬物としての応用
JP6866967B2 (ja) サイクリン依存性キナーゼｃｄｋ９の新規阻害剤
ES3040060T3 (en) Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts.
CN103351390A (zh) 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
CN110092745B (zh) 一种含芳环的化合物及其应用
CN103547152A (zh) 溴结构域蛋白的抑制剂作为基因表达的调节剂
JP6531167B2 (ja) ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
WO2021083310A1 (zh) 作为非pgp底物的抗癌化合物
CN114710956A (zh) 抑制perk的吡咯并嘧啶化合物
HK1203943A1 (en) Quinazolinedione derivative
KR102690225B1 (ko) 퀴놀린 함유 화합물, 의약 조성물 및 그의 용도
JP7301856B2 (ja) インドールアミン－２，３－ジオキシゲナーゼ阻害剤およびその調製方法と使用
KR20250009417A (ko) 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도
TW202246271A (zh) 氮雜芳基化合物、其製備方法及應用
WO2025131131A1 (zh) Hdac抑制剂、组合物及其用途
RU2824069C2 (ru) Фторсодержащее соединение и его применение в медицине против рака
HK40061701A (en) Fluorine-containing compound and anti-cancer medical use thereof
CN119790048A (zh) 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途
HK40061701B (zh) 含氟化合物及抗癌医药用途
KR20230133396A (ko) Rip2 키나아제 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도
CN113795256A (zh) 治疗癌症的fgfr抑制剂
RU2803116C2 (ru) Хинолинил-содержащее соединение и его фармацевтическая композиция и применение
WO2025263500A1 (ja) アミノ酸誘導体